Romilkimab could significantly improve skin fibrosis in people with early diffuse cutaneous systemic sclerosis, results of a phase 2 proof-of-concept study suggest.
Findings from the phase II ASSET trial suggest that patients with diffuse cutaneous systemic sclerosis who are treated with abatacept do not experience significantly greater improvements in skin disease than those given placebo.
The Addressing Behavior Change intervention, which can be delivered by dermatologists in less than 3 minutes, is associated with improvements in people’s sun protection behavior that last several months, findings indicate.
Cutaneous adverse reactions resulting from programmed cell death protein 1 inhibitor therapy can occur late after treatment initiation or even after discontinuation, according to findings reported in JAMA Dermatology.
Researchers have identified discrepancies between patient and physician perspectives of bother associated with the different symptoms of psoriatic disease.
Patients with metastatic melanoma who achieve a complete response with pembrolizumab therapy have a low risk for disease progression or death, report researchers who believe that treatment discontinuation is possible in this setting.
The expression of the histone methyltransferase EZH2 correlates with aggressive subtypes of cutaneous basal cell carcinoma, highlighting the possibility that EZH2 may be an actionable target in this malignancy, say researchers.
The nicotinamide adenine dinucleotide biosynthesis inhibitor APO866 does not show efficacy in patients with cutaneous T-cell lymphoma, according to phase II trial results reported in JAMA Dermatology.
In solid-organ transplant recipients (OTRs) diagnosed with cancer post-transplant, treatment with sirolimus reduces the risk of developing a subsequent skin cancer, US investigators report in JAMA Dermatology.
Patients who undergo haematopoietic cell transplantation should be educated on the risk of skin cancer and the need for regular self-examination, US researchers say.
Research suggests that people with non-melanoma skin cancer are at moderately increased risk for developing other primary malignancies in the future, particularly breast and lung cancer and melanoma.
There is significant discordance between the results of allergen-specific skin prick tests and allergen-specific serum immunoglobulin E levels for identifying aeroallergen sensitization in children under the age of 4 years, a study finds.
Demographic, clinical, and procedural factors should not be used to predict the likelihood of progression after regional therapy for “in-transit” or early metastatic melanoma, say researchers.
Research suggests that patients who experience scabies infection may be at increased risk for developing the autoimmune blistering skin condition bullous pemphigoid.